John Douglas Brockman

Dr. John Douglas Brockman

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2016 in JAMA
Verified
Journal Article
Open access
PDF file
MMMartha Clare Morris
Martha Clare Morris
JBJohn Douglas Brockman
John Douglas Brockman
JSJulie A. Schneider
Julie A. Schneider
YWYamin Wang
Yamin Wang
DBDavid A. Bennett
David A. Bennett
OROndine van de Rest
Ondine van de Rest
Quiz Ref ID Numerous studies have found protective associations between seafood consumption and dementia.1-7 Little is known about the relationship between seafood consumption and brain neuropathology. Seafood is high in the long-chain n-3 fatty acid docosahexaenoic acid (DHA), which has established properties for normal neuronal function.8,9 However, seafood is also a source of mercury, a neurotoxin that impairs neurocognitive development.10 Mercury toxicity is reduced by selenium, an essential nutrient present in seafood that has high binding affinity to mercury.11 In this study, we examined the associations of dementia neuropathologies with dietary n-3 fatty acids and with brain levels of mercury and selenium.

6 February 2006 in Applied Physics Letters
Verified
Journal Article
Closed access
PDF file
CEC. J. Eiting
C. J. Eiting
VKV. Krishnamoorthy
V. Krishnamoorthy
SRS. Rodgers
S. Rodgers
TGT. George
T. George
JRJ. David Robertson
J. David Robertson
JBJohn Douglas Brockman
John Douglas Brockman
A SiC p-i-n junction betavoltaic was fabricated, and electrical power output under irradiation from an 8.5GBq P33 source was monitored over a period of four half-lives of the radioisotope. The open-circuit voltage (VOC) of the device was 2.04±0.02V , and the peak power (Pout) was 0.58±0.02μW (2.1±0.2μW∕cm2) at 1.60V . The conversion efficiency (ηconv) was 4.5%±0.3% and the normalized power output indicates no device degradation over more than 3months (four half-lives of the source).

27 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PKPeter J. Kueffer
Peter J. Kueffer
CMCharles A. Maitz
Charles A. Maitz
AKAslam A. Khan
Aslam A. Khan
SSSeth A. Schuster
Seth A. Schuster
NSNatalia I. Shlyakhtina
Natalia I. Shlyakhtina
MHM. Frederick Hawthorne
M. Frederick Hawthorne
The application of boron neutron capture therapy (BNCT) following liposomal delivery of a 10 B-enriched polyhedral borane and a carborane against mouse mammary adenocarcinoma solid tumors was investigated. Unilamellar liposomes with a mean diameter of 134 nm or less, composed of an equimolar mixture of cholesterol and 1,2-distearoyl- sn -glycero-3-phosphocholine and incorporating Na 3 [1-(2′-B 10 H 9 )-2-NH 3 B 10 H 8 ] in the aqueous interior and K[ nido -7-CH 3 (CH 2 ) 15 -7,8-C 2 B 9 H 11 ] in the bilayer, were injected into the tail veins of female BALB/c mice bearing right flank EMT6 tumors. Biodistribution studies indicated that two identical injections given 24 h apart resulted in tumor boron levels exceeding 67 µg/g tumor at 54 h—with tumor/blood boron ratios being greatest at 96 h (5.68:1; 43 µg boron/g tumor)—following the initial injection. For BNCT experiments, tumor-bearing mice were irradiated 54 h after the initial injection for 30 min with thermal neutrons, resulting in a total fluence of 1.6 × 10 12 neutrons per cm 2 (±7%). Significant suppression of tumor growth was observed in mice given BNCT vs. control mice (only 424% increase in tumor volume at 14 d post irradiation vs. 1551% in untreated controls). In a separate experiment in which mice were given a second injection/irradiation treatment 7 d after the first, the tumor growth was vastly diminished (186% tumor volume increase at 14 d). A similar response was obtained for mice irradiated for 60 min (169% increase at 14 d), suggesting that neutron fluence was the limiting factor controlling BNCT efficacy in this study.

1 August 2017 in Translational Oncology
Verified
Journal Article
Open access
CMCharles A. Maitz
Charles A. Maitz
AKAslam A Khan
Aslam A Khan
PKPeter J Kueffer
Peter J Kueffer
JBJohn Douglas Brockman
John Douglas Brockman
JDJonathan Dixson
Jonathan Dixson
MHM. Frederick Hawthorne
M. Frederick Hawthorne
Boron neutron capture therapy (BNCT) was performed at the University of Missouri Research Reactor in mice bearing CT26 colon carcinoma flank tumors and the results were compared with previously performed studies with mice bearing EMT6 breast cancer flank tumors. Mice were implanted with CT26 tumors subcutaneously in the caudal flank and were given two separate tail vein injections of unilamellar liposomes composed of cholesterol, 1,2-distearoyl-sn-glycer-3-phosphocholine, and K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the lipid bilayer and encapsulated Na3[1-(2`-B10H9)-2-NH3B10H8] within the liposomal core. Mice were irradiated 30 hours after the second injection in a thermal neutron beam for various lengths of time. The tumor size was monitored daily for 72 days. Despite relatively lower tumor boron concentrations, as compared to EMT6 tumors, a 45 minute neutron irradiation BNCT resulted in complete resolution of the tumors in 50% of treated mice, 50% of which never recurred. Median time to tumor volume tripling was 38 days in BNCT treated mice, 17 days in neutron-irradiated mice given no boron compounds, and 4 days in untreated controls. Tumor response in mice with CT26 colon carcinoma was markedly more pronounced than in previous reports of mice with EMT6 tumors, a difference which increased with dose. The slope of the dose response curve of CT26 colon carcinoma tumors is 1.05 times tumor growth delay per Gy compared to 0.09 times tumor growth delay per Gy for EMT6 tumors, indicating that inherent radiosensitivity of tumors plays a role in boron neutron capture therapy and should be considered in the development of clinical applications of BNCT in animals and man.

1 December 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
LMLindsey Mattern
Lindsey Mattern
CCCheng Chen
Cheng Chen
LMLeslie A. McClure
Leslie A. McClure
JBJohn Douglas Brockman
John Douglas Brockman
MCMary Cushman
Mary Cushman
KKKa KaHe
Ka KaHe
Background and Purpose: Despite zinc’s role as an antioxidant and anti-inflammatory agent, prospective studies relating zinc levels to ischemic stroke risk are lacking. To examine the association between serum zinc levels and incidence of ischemic stroke in a US population. Methods: Using a case–cohort study nested within the Reasons for Geographic and Racial Differences in Stroke cohort, participants were randomly selected from the Reasons for Geographic and Racial Differences in Stroke cohort to generate a sub-cohort (n=2346). All incident ischemic stroke cases as of September 2012 (n=660) were included, with 62 incident cases overlapping in the sub-cohort. Serum zinc levels were measured at baseline. Barlow-weighted Cox’s proportional hazards regression models were used to calculate multivariable-adjusted hazard ratios and the corresponding 95% CI of ischemic stroke by serum zinc levels. Results: The median zinc level for the sub-cohort was 121.19 µg/dL (interquartile range, 104.86–140.39 µg/dL). Serum zinc levels were inversely associated with incidence of ischemic stroke after adjustment for potential confounders (quartile 4 versus quartile 1: hazard ratio, 0.78 [95% CI, 0.61–0.98], P =0.03 for trend). When stratified by prespecified factors (sex, race, region), only sex showed a significant modification ( P =0.03 for interaction). The inverse association was more pronounced among females (quartile 4 versus quartile 1: hazard ratio, 0.58 [95% CI, 0.41–0.84], P <0.01 for trend) than males (quartile 4 versus quartile 1: hazard ratio, 1.08 [95% CI, 0.78–1.51], P =0.92 for trend). Conclusions: Serum zinc concentration was inversely associated with incidence of ischemic stroke, especially among women, indicating that low zinc levels may be a risk factor for ischemic stroke.

8 January 2020 in Minerals
Verified
Journal Article
Open access
PDF file
VBVeronica Bradley
Veronica Bradley
BMBenjamin Manard
Benjamin Manard
BRBenjamin Roach
Benjamin Roach
SMShalina C. Metzger
Shalina C. Metzger
KRKayron T. Rogers
Kayron T. Rogers
CHCole Hexel
Cole Hexel
The determination of trace elements, particularly rare earth elements, in uranium ore concentrates (UOCs) is important as the pattern can be indictive ore characteristics. Presented here is a methodology for accurately quantifying rare earth elements (REE) in UOCs. To improve the measurement uncertainty, isotope dilution mass spectrometry (IDMS) was utilized over other quantification techniques such as external calibration or standard addition. The isotopic determinations were measured by inductively coupled plasma-mass spectrometry (ICP-MS). To obtain high-fidelity isotopic measurements, separation of the REE from the uranium matrix was achieved by high-performance ion chromatography (HPIC), reducing the isobaric interferences. After separation, the target analytes were analyzed in two different modalities. For high precision analysis, the separated analytes were collected and measured by ICP-MS in an “offline” fashion. For a rapid approach, the separated analytes were sent directly into an ICP-MS for “online” analysis. These methods have been demonstrated to accurately quantify the REE content in a well-characterized UOC sample.